computer&online trading

PA Singer, ES Tasch, C Stocking, S Rubin, M Siegler and R Weichselbaum Center for Clinical Medical Ethics, University of Chicago, IL.
Patients with localized prostate cancer may be treated with either surgery (radical prostatectomy) or radiotherapy. Although controversial, many physicians believe that surgery offers a higher survival rate. However, the surgical treatment may also produce a higher rate of sexual impotency. Our study assessed how men value survival and sexual potency when asked to trade off one for the other. Using the treatment-choice technique, we interviewed 50 men aged 45 to 70 years without known prostate cancer. At hypothetical rates of survival (90% at 5 years for surgery) and impotency (90% for surgery and 40% for radiotherapy) representing published estimates, 32% of respondents were unwilling to trade off any survival, but 68% were willing to trade off a 10% or greater advantage in 5-year survival (by choosing radiotherapy) to maintain sexual potency. The median 5-year survival traded off was 10% (range, 0% to 80%). Willingness to trade off survival for sexual potency was significantly related to level of education, but not to age, interest in sex, frequency of sexual intercourse, or ability to achieve erection. We conclude that some men may choose treatment with lower long-term survival to increase their chance of remaining sexually potent. Because these men may be difficult to identify in clinical practice, physicians should thoroughly discuss both surgery and radiotherapy options with patients who have localized prostate cancer.
This article has been cited by other articles:

M. J. Leonardi, M. L. McGory, and C. Y. KoQuality of Care Issues in Colorectal CancerClin. Cancer Res., November 15, 2007; 13(22): 6897s - 6902s.
K. E. Bremner, C. A. K. Y. Chong, G. Tomlinson, S. M. H. Alibhai, and M. D. KrahnA Review and Meta-Analysis of Prostate Cancer UtilitiesMed Decis Making, May 1, 2007; 27(3): 288 - 298. [Abstract] [PDF]

J. J. van Tol-Geerdink, P. F.M. Stalmeier, E. N.J.T. van Lin, E. C. Schimmel, H. Huizenga, W. A.J. van Daal, and J.-W. LeerDo Patients With Localized Prostate Cancer Treatment Really Want More Aggressive Treatment?J. Clin. Oncol., October 1, 2006; 24(28): 4581 - 4586. [Abstract] [Full Text] [PDF]

M. McNaughton-Collins, E. Walker-Corkery, and M. J. BarryHealth-Related Quality of Life, Satisfaction, and Economic Outcome Measures in Studies of Prostate Cancer Screening and Treatment, 1990-2000J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 78 - 101. [Abstract] [Full Text] [PDF]

C. D. Karkos, A. Wood, I. A. Bruce, P. D. Karkos, M. S. Baguneid, and M. E. LambertErectile Dysfunction After Open Versus Angioplasty Aortoiliac Procedures: A Questionnaire SurveyVascular and Endovascular Surgery, March 1, 2004; 38(2): 157 - 165. [Abstract] [PDF]

S. M.H. Alibhai, G. Naglie, R. Nam, J. Trachtenberg, and M. D. KrahnDo Older Men Benefit From Curative Therapy of Localized Prostate Cancer?J. Clin. Oncol., September 1, 2003; 21(17): 3318 - 3327. [Abstract] [Full Text] [PDF]

K. L. Kilbridge, B. F. Cole, J. M. Kirkwood, F. G. Haluska, M. A. Atkins, J. C. Ruckdeschel, D. E. Sock, R. F. Nease Jr, and J. C. WeeksQuality-of-Life-Adjusted Survival Analysis of High-Dose Adjuvant Interferon Alfa-2b for High-Risk Melanoma Patients Using Intergroup Clinical Trial DataJ. Clin. Oncol., March 1, 2002; 20(5): 1311 - 1318. [Abstract] [Full Text] [PDF]

A Bowling and S EbrahimMeasuring patients' preferences for treatment and perceptions of riskQual. Saf. Health Care, September 1, 2001; 10(90001): i2 - 8. [Full Text] [PDF]

S. R. Galper, S. J. Lee, M. L. Tao, S. Troyan, C. M. Kaelin, J. R. Harris, and J. C. WeeksPatient Preferences for Axillary Dissection in the Management of Early-Stage Breast CancerJ Natl Cancer Inst, October 18, 2000; 92(20): 1681 - 1687. [Abstract] [Full Text] [PDF]

M. Roach III, D. Reese, V. Weinberg, E. J. Small, P. R. Carroll, F. Boccardo, and A. RubagottiIs the Use of Anti-Androgen Monotherapy Appropriate in Patients With Advanced Prostate Cancer?J. Clin. Oncol., January 14, 2000; 18(2): 448 - 448. [Full Text]

G. B. Chapman, A. S. Elstein, T. M. Kuzel, R. Sharifi, R. B. Nadler, A. Andrews, and C. L. BennettProstate Cancer Patients' Utilities for Health States: How It Looks Depends on Where You StandMed Decis Making, August 1, 1998; 18(3): 278 - 286. [Abstract] [PDF]

J. C. Weeks, E. F. Cook, S. J. O'Day, L. M. Peterson, N. Wenger, D. Reding, F. E. Harrell, P. Kussin, N. V. Dawson, A. F. Connors Jr, et al.Relationship Between Cancer Patients' Predictions of Prognosis and Their Treatment PreferencesJAMA, June 3, 1998; 279(21): 1709 - 1714. [Abstract] [Full Text] [PDF]

A. S. DetskyRegional Variation in Medical CareN. Engl. J. Med., August 31, 1995; 333(9): 589 - 590. [Full Text]

A.M. Stiggelbout, G.M. Kiebert, J. Kievit, J.W.H. Leer, G. Stoter, and J.C.J.M. De HaesUtility Assessment in Cancer Patients: Adjustment of Time Tradeoff Scores for the Utility of Life Years and Comparison with Standard Gamble ScoresMed Decis Making, February 1, 1994; 14(1): 82 - 90. [Abstract] [PDF]

TREATMENT DECISIONS: TRADING QUANTITY FOR QUALITY OF LIFEJournal Watch (General), February 26, 1991; 1991(226): 3 - 3. [Full Text]